GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Birc5 | decreases expression | EXP | | 6480464 | CTD | Topotecan results in decreased expression of BIRC5 mRNA | PMID:25729387 | Birc5 | multiple interactions | EXP | | 6480464 | CTD | [oxaliplatin co-treated with Topotecan] results in decreased expression of BIRC5 mRNA | PMID:25729387 | Birc5 | increases degradation | ISO | Birc5 (Mus musculus) | 6480464 | CTD | Topotecan results in increased degradation of BIRC5 protein | PMID:19812371 | Birc5 | multiple interactions | ISO | Birc5 (Mus musculus) | 6480464 | CTD | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Topotecan results in increased degradation of BIRC5 protein]; TRP53 inhibits the reaction [Topotecan results in increased degradation of BIRC5 protein] | PMID:19812371 | Birc5 | multiple interactions | ISO | BIRC5 (Homo sapiens) | 6480464 | CTD | [Topotecan co-treated with pifithrin] results in increased degradation of BIRC5 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[pifithrin co-treated with Topotecan] results in increased degradation of BIRC5 protein] | PMID:19812371 | |
Go Back to source page | Continue to Ontology report |